Thaçi, D <br/><br/>
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).  [electronic resource] 

 -  The British journal of dermatology  08 2020 
 - 265-275 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/bjd.18696  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Fumarates--adverse effects<br/>Humans<br/>Psoriasis--drug therapy<br/>Quality of Life<br/>Severity of Illness Index<br/>Treatment Outcome